We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Post Marketing Surveillance Study of Cuprimine

Expanded access is no longer available for this treatment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01374282
First Posted: June 15, 2011
Last Update Posted: October 22, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
  Purpose
Cuprimine (penicillamine) was made available in the Philippines by the Sponsor under a Compassionate Special Permit issued by the Bureau of Food and Drugs. Physicians were able to request the drug for their patients from the Sponsor. A Clinical Study Report form was completed for each purchase of Cuprimine.

Condition Intervention
Scleroderma Drug: Cuprimine (penicillamine)

Study Type: Expanded Access     What is Expanded Access?
Official Title: Post Marketing Surveillance Study of Cuprimine (MK-0172-001)

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Intervention Details:
    Drug: Cuprimine (penicillamine)
    Dosage determined by the physician based on indication for treatment
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- None

Exclusion Criteria:

- None

  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01374282     History of Changes
Other Study ID Numbers: 0172-001
First Submitted: June 14, 2011
First Posted: June 15, 2011
Last Update Posted: October 22, 2015
Last Verified: October 2015

Additional relevant MeSH terms:
Penicillamine
Antidotes
Protective Agents
Physiological Effects of Drugs
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents